<I>BOC</I> Is a Modifier Gene in Holoprosencephaly
Total Page:16
File Type:pdf, Size:1020Kb
Received: 12 May 2017 Revised: 20 June 2017 Accepted: 28 June 2017 DOI: 10.1002/humu.23286 BRIEF REPORT BOC is a modifier gene in holoprosencephaly Mingi Hong1∗ Kshitij Srivastava2∗ Sungjin Kim1 Benjamin L. Allen3 Daniel J. Leahy4 Ping Hu2 Erich Roessler2 Robert S. Krauss1† Maximilian Muenke2† 1Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York 2Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 3Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan 4Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas Correspondence Robert S. Krauss (for editorial communication), Abstract Department of Cell, Developmental and Regen- Holoprosencephaly (HPE), a common developmental defect of the forebrain and midface, has a erative Biology, Icahn School of Medicine at complex etiology. Heterozygous, loss-of-function mutations in the sonic hedgehog (SHH) pathway Mount Sinai, New York, New York 10029. Email: [email protected] are associated with HPE. However, mutation carriers display highly variable clinical presentation, Maximilian Muenke, Medical Genetics Branch, leading to an “autosomal dominant with modifier” model, in which the penetrance and expressiv- National Human Genome Research Institute, ity of a predisposing mutation is graded by genetic or environmental modifiers. Such modifiers National Institutes of Health, Bethesda, Mary- land 20892. have not been identified. Boc encodes a SHH coreceptor and is a silent HPE modifier gene in mice. Email: [email protected] Here, we report the identification of missense BOC variants in HPE patients. Consistent with these ∗Mingi Hong and Kshitij Srivastava contributed alleles functioning as HPE modifiers, individual variant BOC proteins had either loss- or gain-of- equally to this work. function properties in cell-based SHH signaling assays. Therefore, in addition to heterozygous † Robert S. Krauss and Maximilian Muenke con- loss-of-function mutations in specific SHH pathway genes and an ill-defined environmental com- tributed equally to this work as senior authors. ponent, our findings identify a third variable in HPE: low-frequency modifier genes, BOC being the Contract grant sponsors: NIH (DE024748, GM118751, CA198074); Cancer Prevention first identified. and Research Institute of Texas (CPRIT) (award RR160023); Division of Intramural Research, KEYWORDS NHGRI, NIH. birth defect, BOC, gene variant, holoprosencephaly, modifier gene, sonic hedgehog Communicated by Hildegard Kehrer-Sawatzki Many structural birth defects are thought to arise from a complex com- nature. While bona fide pathogenic mutations in SHH and other genes bination of genetic and environmental risk factors (Krauss & Hong associated with HPE continue to be cataloged, identification of poten- 2016). Holoprosencephaly (HPE; MIM# 236100), a common and often tial HPE modifiers is in its infancy. devastating defect in midline patterning of the forebrain and mid- The binding of SHH to its primary cell surface receptor PTCH1 face, is a prototypical example. HPE encompasses a phenotypic spec- (MIM# 601309) initiates a signaling cascade to modulate GLI tran- trum that ranges from failure to partition the forebrain into hemi- scription factors, which induce expression of pathway target genes spheres and cyclopia, to mild midfacial anomalies that occur with- (Lee et al., 2016). Among the direct target genes is GLI1 (MIM# out forebrain involvement (Geng & Oliver, 2009). Heterozygous, loss- 165220) itself. SHH and PTCH1 both bind to several coreceptors, of-function mutations in components of the sonic hedgehog (SHH; including CDON (MIM# 608707), BOC (MIM# 608708), and GAS1 MIM# 600725) signaling pathway are frequently associated with HPE (MIM# 139185) (Bae et al., 2011; Izzi et al., 2011; Tenzen et al., 2006). (Roessler & Muenke, 2010). However, highly variable clinical presenta- Studies with knockout mice revealed that these three coreceptors have tion is seen in mutation carriers, even within pedigrees. Furthermore, overlapping and partially redundant function in supporting SHH sig- in many “sporadic” cases, mutations in SHH are inherited from a par- naling during development; embryos lacking all three have a nearly ent with little or no clinical manifestation (Solomon et al., 2012). Sta- complete loss of pathway activity (Allen et al., 2011). Heterozygous, tistical analyses have led to an “autosomal dominant with modifier” loss-of-function mutations in CDON and GAS1 have been identified in model, in which the penetrance and expressivity of a predisposing het- HPE patients (Bae et al., 2011; Pineda-Alvarez et al., 2012; Ribeiro, erozygous mutation is graded by modifiers (Roessler, Vélez, Zhou, & Quiezi, Nascimento, Bertolacini, & Richieri-Costa, 2010). Consistent Muenke, 2012). Such modifiers may be genetic or environmental in with these observations, mice with targeted mutations in either Cdon Human Mutation. 2017;38:1464–1470. wileyonlinelibrary.com/journal/humu c 2017 Wiley Periodicals, Inc. 1464 HONG ET AL. 1465 or Gas1 display a range of HPE phenotypes (Allen, Tenzen, & McMa- vectors encoding four of the HPE-associated BOC variants: hon, 2007; Hong & Krauss, 2012; Martinelli & Fan, 2007; Seppala et al., p.Arg533Leu, p.Gly556Glu, p.Arg697Pro, and p.Pro828Arg. The 2007; Zhang, Kang, Cole, Yi, & Krauss, 2006). In contrast, mice lacking p.Arg533Leu and p.Gly556Glu substitutions are in Fn3 repeat 1, Boc do not have HPE (Zhang, Hong, Bae, Kang, & Krauss, 2011). How- p.Arg697Pro is in the linker region between Fn3 repeats 1 and 2, and ever, genetic removal of Boc from Cdon−/− or Gas1−/− mice exacerbates p.Pro828Arg is in the linker region between Fn3 repeat 3 and the their HPE phenotype (Seppala, Xavier, Fan, & Cobourne, 2014; Zhang transmembrane region. These variants were selected because: (1) they et al., 2011). Therefore, Boc functions as a silent HPE modifier gene in were located in the Fn repeat region of BOC, which is critical for Shh mice. Here, we address the potential role of BOC in HPE pathogenesis signaling (Song, Holtz, Pinskey, & Allen, 2015); and (2) they resemble in humans. similarly located, HPE-associated, loss-of-function, missense muta- We performed high-throughput screening of BOC (NM_033254.3) tions in CDON in that they were highly nonconservative substitutions for 360 HPE patients using high-resolution melting, as described (Kau- in evolutionarily conserved residues (Bae et al., 2011). Prioritization of var et al., 2011). Additionally, 384 unrelated individuals were screened these variants was not based on either retrospective allele frequency as controls. HPE and control samples with melting profiles that devi- or ANNOVAR annotation criteria, which were not available at the time ated from wild-type melting curves were directly sequenced for vari- of study design. ant confirmation. A total of eight different amino acid substitution Each variant was expressed at easily detectable levels when tran- variants in BOC were identified in HPE patients, including one that siently transfected in HEK293T cells (Fig. 1B). When expressed in TKO was found in two unrelated patients and two that were present in a cells subsequently treated with SHH, the p.Arg533Leu, p.Arg697Pro, single patient (Table 1). There are over 400 BOC missense variants and p.Pro828Arg variants were similar to wild-type BOC in having reported in ExAC. We note that most of the variants we identified are little ability to promote ligand-dependent Gli1 expression (Fig. 1C). rare (Table 1), including p.Gly556Glu, which has not been previously Surprisingly, the p.Gly556Glu variant had substantial activity in this reported. An exception is p.Pro828Arg, which has a minor allele fre- assay, conferring on BOC the ability to promote SHH signaling. There- quency of 0.0017, more common than the ∼1:10,000 birth frequency fore, p.Gly556Glu is a ligand-dependent, gain-of-function mutant. When of HPE (Leoncini et al., 2008), and consistent with possible function as lysates of cells expressing wild-type BOC or the HPE-associated vari- a modifier allele. All individuals were also studied for the four genes ants were analyzed by Western blotting after conditions of limited pro- most commonly screened in HPE (SHH, ZIC2 (MIM# 603073), SIX3 teolysis, p.Gly556Glu did not produce a product formed by the others (MIM# 603714), and TGIF (MIM# 602630)). One patient had a trun- (Fig. 1D). This result suggests that p.Gly556Glu may have an altered cating mutation in ZIC2, and another patient had a deletion of TGIF conformation that contributes to its gain of function. A similar obser- (Table 1). vation was made for some of the HPE-associated CDON variants that To explore the functional consequences of HPE-associated BOC displayed a loss of function (Bae et al., 2011). variants, we developed a cell-based assay for BOC activity. Exogenous The ability of p.Gly556Glu to confer SHH-dependent Gli1 expres- expression of BOC had little ability to enhance SHH signaling in wild- sion to TKO cells offered an opportunity to assess whether the type mouse embryo fibroblasts (MEFs) or even Cdon−/−;Boc−/− MEFs other three HPE-associated variants might have the anticipated (not shown). To work in as sensitive a cell system as possible, we used loss-of-function property by constructing BOC expression vectors Cdon−/−;Boc−/−;Gas1−/− MEFs (TKO cells) (Mathew et al., 2014). When that harbor the p.Gly556Glu change along with, independently,